The present study evaluated ILD incidence and exacerbation among users of abatacept (T-cell inhibitor), rituximab (B-cell inhibitor), and tocilizumab (interleukin-6 (IL-6) inhibitor) compared with anti-TNFα agents in a cohort of adult RA patients who previously had exposure to at least one biologic therapy. The gene discussed is TNF; the disease is rheumatoid arthritis.